Highlights of the NCCN Oncology Research Program
The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program’s establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
This feature highlights an NCCN study funded through the grant mechanism.
For more information on specific trials, including patient selection criteria, use the contact information listed with each study.
For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, go to www.nccn.org/education-research/nccn-oncology-research-program/orp-main-page.
2025
- April
CV CARE: CardioVascular Care of Androgen-Related Effects in Patients With Prostate Cancer - March
A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer - February
SyMPLER: Patient- and Caregiver-Triggered Palliative Referrals via an Electronic Symptom Monitoring Program - January
A Phase II Study of Neratinib in Combination With Chemotherapy/Trastuzumab/Pembrolizumab in HER2-Overexpressing Gastroesophageal Cancers
